Skip to main content
رجوع
CSPHF logo

CStone Pharmaceuticals

جودة البيانات: 100%
ذروة شراء
CSPHF
OTC Healthcare Biotechnology
KWD 0.86
KWD 0.00 (0.00%)
القيمة السوقية: 1.26B
نطاق اليوم
KWD 0.86 KWD 0.86
نطاق 52 أسبوعًا
KWD 0.52 KWD 1.00
حجم التداول
852
متوسط 50 يوم / 200 يوم
KWD 0.80 / KWD 0.80
الإغلاق السابق
KWD 0.86

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -13.8 0.3
P/B 3.5 2.9
ROE % -22.2 3.7
Net Margin % -22.4 3.8
Rev Growth 5Y % -20.9 10.0
D/E 1.0 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2028 KWD 0.000
KWD 0.000 – KWD 0.000
590 M 0
FY2027 KWD 1.202
KWD 0.928 – KWD 1.388
2.6 B 1
FY2026 -KWD 0.160
-KWD 0.184 – -KWD 0.123
450 M 1

النقاط الرئيسية

Revenue declined -20.87% annually over 5 years
Negative free cash flow of -343.18M
PEG of 0.31 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 8.66%
Capital efficient — spends only 0.00% of revenue on capex

النمو

Revenue Growth (5Y)
-20.87%
Revenue (1Y)-12.21%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-22.23%
ROIC-9.55%
Net Margin-22.40%
Op. Margin-22.52%

الأمان

Debt / Equity
0.98
Current Ratio1.60
Interest Coverage-6.05

التقييم

P/E Ratio
-13.79
P/B Ratio3.46
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -12.21% Revenue Growth (3Y) -8.02%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -20.87% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 407.21M Net Income (TTM) -91.21M
ROE -22.23% ROA -6.55%
Gross Margin 58.98% Operating Margin -22.52%
Net Margin -22.40% Free Cash Flow (TTM) -343.18M
ROIC -9.55% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.98 Current Ratio 1.60
Interest Coverage -6.05 Dividend Yield 0.00%
Valuation
P/E Ratio -13.79 P/B Ratio 3.46
P/S Ratio 3.09 PEG Ratio 0.31
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.26B Enterprise Value 1.23B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 407.21M 463.84M 481.36M 243.72M 1.04B
Net Income -91.21M -367.23M -902.68M -1.92B -1.22B
EPS (Diluted) -0.07 -0.29 -0.77 -1.65 -1.17
Gross Profit 240.15M 304.30M 278.38M 136.89M 797.41M
Operating Income -91.69M -579.85M -912.15M -1.83B -1.09B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 1.39B 1.66B 1.64B 2.27B 3.76B
Total Liabilities 1.03B 1.21B 1.19B 1.06B 808.29M
Shareholders' Equity 363.87M 456.83M 449.33M 1.21B 2.95B
Total Debt 355.97M 363.45M 286.29M 174.20M 83.86M
Cash & Equivalents 387.94M 996.67M 558.68M 742.72M 3.02B
Current Assets 1.09B 1.33B 1.25B 1.96B 3.57B
Current Liabilities 682.01M 850.34M 946.48M 932.95M 727.05M